Experimental drug aims to slow kidney damage in proteinuria patients
NCT ID NCT02343094
Summary
This study tested whether a drug called sodium phenylbutyrate could reduce levels of a specific harmful protein (NGAL/Lcn2) in the urine of people with chronic kidney disease and high protein loss. The goal was to see if reducing this protein could help slow the progression of kidney damage. The trial involved 26 adult patients who already had significant proteinuria.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROTEINURIC DISEASES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hôpital Necker Enfants Malades
Paris, 75015, France
Conditions
Explore the condition pages connected to this study.